The systematic review, “Prevalence and Clinical Significance of FGFR3 Genomic Alterations in Asian Bladder Urothelial Carcinoma,” co-authored by Chandra Sekhar Pedamallu, was published in the Asian Journal of Oncology.
Bladder urothelial carcinoma remains a significant health burden across Asia, with distinct genetic variations compared to other populations. This comprehensive study delves into the genetic landscape of bladder cancer in Asian populations, with a specific focus on the prevalence and implications of FGFR3 genomic alterations. The review highlights that at least 16% of patients exhibit FGFR3 mutations, particularly the S249C hotspot mutation, which are mutually exclusive with TP53 alterations.
These findings reinforce the critical role of molecular profiling in tailoring precision oncology approaches for bladder cancer management.
Read this expertly authored review to learn more about FGFR3 genomic alterations and their impact on bladder cancer treatment in Asian populations and explore the future of precision oncology.Â
Note: No part of this report may be reproduced or distributed without prior written permission.